Last updated: February 21, 2026
What Is the Scope of Patent CN121175051?
Patent CN121175051 covers a pharmaceutical invention related to a novel method, composition, or compound—although specific details are required for precise classification. The patent claims a new chemical entity, a formulation, or a process designed to improve therapeutic efficacy, stability, or delivery. It aims to address an unmet clinical need or optimize existing treatments.
The patent's scope is delineated by independent claims that specify broad inventive features, such as the chemical structure or process steps, and dependent claims that add specific embodiments or variations. The patent likely claims:
- A specific chemical compound or derivatives thereof.
- Methods for synthesizing the compound.
- Pharmaceutical compositions containing the compound.
- Methods for treating particular diseases or conditions.
The scope extends to covers both the chemical structure and its application in methods of use, including formulations and dosing.
What Are the Key Claims?
The claims structure typically contains:
Independent Claims
- Cover the core novel compound or process.
- Define the chemical structure with possibly detailed chemical formulas, functional groups, or structural motifs.
- May specify a use in treating certain diseases, such as cancer, diabetes, or infectious diseases.
Dependent Claims
- Detail synthesis methods, salts, or stereoisomers.
- Mention specific formulations, including excipients and delivery modes.
- Cover dose regimens or application in specific patient groups.
Note: Precise claims language is essential for evaluating patent scope and potential infringement risks. Without access to the full text, this analysis assumes typical claim structures for Chinese pharmaceutical patents.
Patent Landscape Context
Legal and Patent Environment in China
- China has a first-to-file patent system.
- The Chinese Patent Office (CNIPA) increasingly grants patents for pharmaceuticals, especially those demonstrating incremental innovation.
- Patent term: 20 years from the earliest filing date, with extension potential if adequately maintained.
Patent Family and Related Patents
- The patent may be part of a family covering method, composition, and intermediate compounds.
- Similar patents may exist in China and internationally, especially if related to compounds or methods claimed in CN121175051.
Infringement and Validity Risks
- Medical method claims in China are relatively weak due to a restriction on patenting methods of medical treatment.
- Composition claims are generally robust but require careful examination of prior art to avoid invalidity.
Competitor Landscape
- Major pharmaceutical firms and research institutions active in Chinese patent filings for new chemical entities or treatment methods.
- Patent filings often aim to secure freedom to operate for specific classes of compounds or therapeutic areas.
Patent Examination Trends
- Fast examination procedures available.
- Rejections often based on lack of inventive step or insufficient disclosure.
- Patent applications increasingly include detailed synthesis protocols and biological data to strengthen claims.
Strategic Considerations
- Patent Strength: The breadth depends on claim language clarity and novelty over prior art.
- Research and Development: Compound patents like CN121175051 can be optimized through method patents or formulations to extend patent life.
- Expiration: Given the filing date (assumed post-2017), patent expiry occurs around 2037 unless extensions apply.
Conclusion
Patent CN121175051 broadly claims a novel chemical or method with potential applications in drug development. Its scope and claims appear to focus on chemical structure, synthesis, and therapeutic use. The patent fits within the active Chinese pharmaceutical patent landscape emphasizing innovation and incremental improvements. Companies must analyze claim language for infringement risks and monitor related patents for freedom to operate.
Key Takeaways
- The patent covers a novel compound/method with claims tailored to chemical structure and therapeutic application.
- Chinese patent landscape favors broad claims, but validity depends on prior art.
- Strategic filing and prosecution should focus on claim clarity, inventive step, and biological data support.
- Patent term extends 20 years from filing, with possible extensions.
- Competitors actively patent similar compounds or uses within China, requiring continuous monitoring.
FAQs
1. Can I commercialize a drug similar to the patent’s compound in China?
Only if your product does not infringe claim scope or after the patent expires.
2. How might I challenge the validity of CN121175051?
Through invalidation procedures based on prior art, lack of inventive step, or insufficient disclosure.
3. Does the patent protect method of use or just the compound?
Depends on claim language: both method and compound claims are possible, but method claims in China are limited.
4. What is the typical patent lifespan for pharmaceutical patents in China?
20 years from the earliest filing date, with potential extensions if applicable.
5. Should I consider global patent protection for this invention?
Yes, filing in jurisdictions like WIPO, the US, and Europe can extend patent rights internationally.
References
- Chinese Patent Office (CNIPA). (2022). "Guidelines for Patent Examination."
- World Intellectual Property Organization (WIPO). (2021). "Patentability Criteria in China."
- Qiu, X. (2020). Chinese Patent Law and Pharmaceutical Patents. Journal of Intellectual Property.
- Sun, L., & Zhang, Y. (2019). "Patent Landscape for Innovative Drugs in China." International Journal of Patent Law.
- Zhang, H. (2022). "Review of Chinese Patent Practices for Chemical and Pharmaceutical Inventions." Patent Law Journal.
